Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone versus metformin as first-line therapy for type 2 diabetes in Indigenous Australians
ACTRN12607000135415Phase 4Not yet recruiting
- Sponsor
- Menzies School of Health Research
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pioglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Menzies School of Health Research. Primary endpoints: HbA1c values, Weight gain and 2 more. Planned start Aug 2008; status: not yet recruiting.
02
Drugs
pioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12607000135415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000135415.